Last reviewed · How we verify

NCT05921552

Senior Adult Hepatobiliary Prehab Study

Active, enrolled NA Last updated 4 December 2025
What this trial tests

NA trial testing Resistance Training in Hepatobiliary Cancer in 25 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
26 June 2023
Primary endpoint
19 November 2026
19 November 2026

Quick facts

Lead sponsorH. Lee Moffitt Cancer Center and Research Institute
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment25
Start date26 June 2023
Primary completion19 November 2026
Estimated completion19 November 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Who can join

65 and older, any sex, with Hepatobiliary Cancer or Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate an exercise program for individuals with hepatobiliary cancer planning for surgery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Exercise and Nutrition Interventions for Prehabilitation in Hepato-Pancreato-Biliary Cancers: A Narrative Review.
    Christopher CN, Kang DW, Wilson RL, Gonzalo-Encabo P, et al · · 2023 · cited 13× · PMID 38140303 · DOI 10.3390/nu15245044

Verify or expand the search:

Other trials of Resistance Training

Trials testing the same drug.

Other recruiting trials for Hepatobiliary Cancer

Currently open trials in the same condition.

Other H. Lee Moffitt Cancer Center and Research Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05921552.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing